Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Long-acting anti-TNF? conjugates to minimize osteolysis around joint replacement devices

Award Number: R43AR071857
ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/13/2017
PERIOD OF PERFORMANCE END DATE: 08/31/2019

Group Awards By:

View Award Description

Long-acting anti-TNF? conjugates to minimize osteolysis around joint replacement devices - Project Summary As of 2015, more than 7 million Americans were living with an implanted artificial joint. While these devices improve the lives of many, over 250,000 of these individuals will eventually require a costly and painful revision surgery due to aseptic loosening of the device from the bone. This type of device failure typically stems from the immune response to microparticles that are generated due to wear between the articular surfaces. Thus, a comprehensive approach to increasing the functional life span of joint replacement devices must include a strategy for controlling the body's response to these particles. Tumor necrosis factor-α (TNFα) has emerged as a compelling target for controlling the foreign body response to microparticles. However, the half-life of anti- TNF therapeutics acting from within the joint is short, and thus this strategy is limited by the need for frequent (e.g., weekly) drug administration for effective treatment. To enable longer acting anti-TNF drug activity, Valitor has developed a patented platform technology for generating soluble clusters of therapeutic antibodies attached to single-chain biopolymers. In contrast to other methods of protein-polymer conjugation (e.g., PEGylation), our method of conjugation generates substantially larger conjugates with enhanced drug potency. In fact, our anti-TNFα antibody conjugates (mvAntiTNF) are even larger than the tissue meshwork that lines the inside of the joint, and therefore we anticipate mvAntiTNF will be retained within the joint at least 12 times longer than an unmodified antibody after intra-articular injection. During Phase I, we will verify that increasing the molecular size of mvAntiTNF conjugates will provide longer-acting inhibition of the immune responses to microparticles in the joint space and prevent implant loosening over time. Our proposed study will provide proof-of-concept that anti-TNF conjugates can generate sustained treatment effects in the joint. We expect this mvAntiTNF therapy will follow a well-defined route to FDA market approval and commercialization, which we will continue during the next phase of this project.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2017	VALITOR, INC.	820 HEINZ AVE	BERKELEY	CA	94710	ALAMEDA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	1/14/2020	NEW	$0
														Subtotal = $0

Issue Date FY: 2017 ( Subtotal = $224,934 )
2017	2017	VALITOR, INC.	820 HEINZ AVE	BERKELEY	CA	94710	ALAMEDA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	9/12/2017	NEW	$224,934
														Subtotal = $224,934

Grand Total All Awards = $224,934

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Long-acting anti-TNF? conjugates to minimize osteolysis around joint replacement devices

Award Number: R43AR071857

ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/13/2017

PERIOD OF PERFORMANCE END DATE: 08/31/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer